Agonist-activated alpha nu beta 3 on platelets and lymphocytes binds to the matrix protein osteopontin

被引:81
作者
Bennett, JS
Chan, C
Vilaire, G
Mousa, SA
DeGrado, WF
机构
[1] UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104
[2] DUPONT MERCK PHARMACEUT CO,WILMINGTON,DE 19880
关键词
D O I
10.1074/jbc.272.13.8137
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
The phosphorylated acidic glycoprotein osteopontin is present in the extracellular matrix of atherosclerotic plaques and the wall of injured but not normal arteries. To determine if osteopontin could serve as a substrate for platelet adhesion, we measured the adherence of resting and agonist-stimulated human platelets to immobilized recombinant human osteopontin. Agonist-stimulated but not resting platelets bound to osteopontin by a process that was mediated primarily by alpha v beta 3. alpha v beta 3-mediated adherence occurred at physiologic concentrations of calcium and was inhibited by an alpha v beta 3-selective cyclic peptide. Assays using phorbol myristate acetate-stimulated transfected B lymphocytes expressing both alpha v beta 3 and alpha IIb beta 3 confirmed that activated alpha v beta 3 not activated alpha IIb beta 3 was responsible for the cellular adherence we measured. These studies indicate that alpha v beta 3 can reside on the cell surface in an inactive state and can be converted to a ligand binding conformation by cellular agonists. Moreover, they suggest that platelet adherence to osteopontin mediated by activated alpha v beta 3 could play a role in anchoring platelets to disrupted atherosclerotic plaques and the walls of injured arteries. By inhibiting alpha v beta 3 function, it may be possible to inhibit platelet-mediated vascular occlusion with a minimal effect on primary hemostasis.
引用
收藏
页码:8137 / 8140
页数:4
相关论文
共 33 条
[1]
Type II' to type I beta-turn swap changes specificity for integrins [J].
Bach, AC ;
Espina, JR ;
Jackson, SA ;
Stouten, PFW ;
Duke, JL ;
Mousa, SA ;
DeGrado, WF .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1996, 118 (01) :293-294
[2]
A COLORIMETRIC METHOD FOR THE MEASUREMENT OF PLATELET-ADHESION IN MICROTITER PLATES [J].
BELLAVITE, P ;
ANDRIOLI, G ;
GUZZO, P ;
ARIGLIANO, P ;
CHIRUMBOLO, S ;
MANZATO, F ;
SANTONASTASO, C .
ANALYTICAL BIOCHEMISTRY, 1994, 216 (02) :444-450
[3]
INHIBITION OF FIBRINOGEN BINDING TO STIMULATED HUMAN-PLATELETS BY A MONOCLONAL-ANTIBODY [J].
BENNETT, JS ;
HOXIE, JA ;
LEITMAN, SF ;
VILAIRE, G ;
CINES, DB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (09) :2417-2421
[4]
EXPOSURE OF PLATELET FIBRINOGEN RECEPTORS BY ADP AND EPINEPHRINE [J].
BENNETT, JS ;
VILAIRE, G .
JOURNAL OF CLINICAL INVESTIGATION, 1979, 64 (05) :1393-1401
[5]
BENNETT JS, 1996, TRENDS CARDIOVAS MED, V16, P31
[6]
CHERESH DA, 1987, J BIOL CHEM, V262, P17703
[7]
INHIBITION OF NEOINTIMAL HYPERPLASIA BY BLOCKING ALPHA(V)BETA(3), INTEGRIN WITH A SMALL PEPTIDE ANTAGONIST GPENGRGDSPCA [J].
CHOI, ET ;
ENGEL, L ;
CALLOW, AD ;
SUN, SP ;
TRACHTENBERG, J ;
SANTORO, S ;
RYAN, US .
JOURNAL OF VASCULAR SURGERY, 1994, 19 (01) :125-134
[8]
COLLER BS, 1991, BLOOD, V77, P75
[9]
A NEW MURINE MONOCLONAL-ANTIBODY REPORTS AN ACTIVATION-DEPENDENT CHANGE IN THE CONFORMATION AND OR MICROENVIRONMENT OF THE PLATELET GLYCOPROTEIN IIB/IIIA COMPLEX [J].
COLLER, BS .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (01) :101-108
[10]
A MURINE MONOCLONAL-ANTIBODY THAT COMPLETELY BLOCKS THE BINDING OF FIBRINOGEN TO PLATELETS PRODUCES A THROMBASTHENIC-LIKE STATE IN NORMAL PLATELETS AND BINDS TO GLYCOPROTEINS-IIB AND OR GLYCOPROTEIN-IIIA [J].
COLLER, BS ;
PEERSCHKE, EI ;
SCUDDER, LE ;
SULLIVAN, CA .
JOURNAL OF CLINICAL INVESTIGATION, 1983, 72 (01) :325-338